Kalamazoo, Mich. (PRWEB) April 09, 2015
Armune BioScience has announced the appointment of Dr. Robert Reinhardt to the position of Medical Advisor. An experienced clinician and industry executive, Dr. Reinhardt will support the launch of the company’s lead product, Apifiny™ - the only tumor specific, non-PSA blood test designed to aid clinicians in the detection of prostate cancer.
In addition to his training as a physician, Dr. Reinhardt is a highly experienced business executive. He previously served as the Chief Medical Officer of Phadia US Inc., which was purchased by Thermo Fisher Scientific in 2011. After earning his medical degree from Michigan State University, Dr. Reinhardt spent many years in academic family medicine at Brown University, the University of Michigan, and then at MSU. Currently, he is a Clinical Associate Professor of Family Medicine at the Western Michigan University Homer Stryker M.D. School of Medicine.
“I’m excited to be joining Armune as the company begins to make available the first of many innovative tests to address the large unmet need in cancer diagnostic and prognostic testing,” said Dr. Reinhardt. “The company’s unique technology developed out of research from the University of Michigan has the potential to significantly improve care and reduce the cost of care in many areas of cancer.”
“Dr. Reinhardt’s breadth of experience as a physician and respected industry executive will add tremendous value to our customers,” said Armune President and CEO David A. Esposito. “We are seeing significant interest from the healthcare community around the potential benefits of Apifiny to aid in the detection of prostate cancer and we are grateful to have Dr. Reinhardt join our company at this important stage in our growth.”
Armune BioScience, Inc. develops and commercializes autoantibody technology licensed from the University of Michigan that was developed under the direction of Arul Chinnaiyan, MD, PhD. In the coming weeks, Armune will be launching Apifiny in the United States from its laboratory in Ann Arbor, MI. Clinicians and patients interested in gaining access to Apifiny should call 844-427-6863 or request information from the company’s website at http://www.armune.com
Armune continues to raise funds through its current Series A round of investment to support the growth of the business. Interested investors should contact Eli Thomssen, Chief Business Officer, at elthomssen(at)armune(dot)com or by telephone, 269-491-6431.
About Armune BioScience (http://www.armune.com)
Armune BioScience, Inc. is a medical diagnostics company that develops and commercializes unique proprietary technology exclusively licensed from the University of Michigan for diagnostic and prognostic tests for prostate, lung and breast cancers. The Company was founded by the Apjohn Group, LLC (http://www.apjohngroup.com), a business accelerator founded by experienced health care executives that brings together valuable resources of management talent and angel/seed financing, and a group of experienced life science professionals. Armune was incorporated as a Delaware Corporation with corporate headquarters in Kalamazoo, MI and a research and commercial laboratory in Ann Arbor, MI.